Trump diagnosed with common vein condition after ankle swelling raises concerns

Trump diagnosed with common vein condition after ankle swelling raises concerns


First Lady Melania Trump, President Donald Trump, FIFA President Gianni Infantino and his wife, Leena Al Ashqar, attend the FIFA Club World Cup 2025 final football match between England’s Chelsea and France’s Paris Saint-Germain at MetLife Stadium in East Rutherford, New Jersey, July 13, 2025.

Charly Triballeau | AFP | Getty Images

President Donald Trump underwent a comprehensive medical exam that revealed he has a common vein disorder but cleared him of more serious illnesses, the White House said Thursday.

The White House disclosed the 79-year-old president’s medical information in response to speculation after photos showed Trump with swollen ankles.

Press secretary Karoline Leavitt said Trump noticed the swelling in recent weeks and received a thorough evaluation by the White House medical unit.

He was diagnosed with chronic venous insufficiency, which Leavitt described as a “benign and common condition, particularly in individuals over the age of 70.”

Chronic venous insufficiency occurs when a person’s leg veins are damaged, restricting circulation and causing blood to pool in the legs, according to the Cleveland Clinic.

Chronic venous insufficiency affects about 1 in 20 adults, and the risk increases with age, according to the clinic.

Leavitt said Trump was not in any pain from the condition.

A bruise is visible on President Donald Trump’s right hand that appeared to be covered with makeup, as Trump waited to greet Crown Prince Salman bin Hamad Al Khalifa of Bahrain as he arrived outside the West Wing of the White House, July 16, 2025.

Mehmet Eser | AFP | Getty Images

Leavitt also addressed bruises periodically visible on the back of Trump’s hand. She said they were caused by irritation from “frequent handshaking,” coupled with his aspirin regimen.

The medical exam found no evidence of deep vein thrombosis or arterial disease, Leavitt said.

Trump’s blood test results were all within “normal limits,” and an echocardiogram confirmed “normal cardiac structure and function” with “no signs of heart failure, renal impairment or systemic illness,” she added.

Leavitt said in Thursday’s briefing that bruising like that seen on Trump’s hands is a common side effect of regularly using aspirin, which Trump takes as part of a “standard cardiovascular prevention regimen.”

“The president remains in excellent health, which I think all of you witness on a daily basis here,” she said.

White House physician Sean Barbabella wrote in an April memo that Trump “remains in excellent physical health” and is “fully fit” to perform the duties of the presidency.

Read Thursday’s full memo from Barbabella below.

President Donald Trump’s health status update.

Courtesy: The White House

This is developing news. Please check back for updates.



Source

CDC takes down more than a dozen webpages on sexual and gender identity, health equity
Health

CDC takes down more than a dozen webpages on sexual and gender identity, health equity

A sign for the CDC sits outside of their facility at the Centers for Disease Control and Prevention Roybal campus in Atlanta, Georgia, U.S., May 30, 2025. Megan Varner | Reuters More than a dozen pages on the Centers for Disease Control and Prevention website related to sexual and gender identity, health equity, and other […]

Read More
We’re buying the dip in a health and life sciences stock that has gone down enough
Health

We’re buying the dip in a health and life sciences stock that has gone down enough

We’re buying 20 more shares of Danaher at roughly $180 each. Following Thursday’s trade, Jim Cramer’s Charitable Trust will own 470 shares of DHR, increasing its weighting to about 2.31% from about 2.22%. While Danaher has certainly been one of a handful of problematic stocks in the portfolio, we are stepping into the name here, […]

Read More
Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial
Health

Roche targets becoming top 3 obesity player as experimental drug enters late-stage trial

The Roche Holding AG headquarters on April 11, 2025, in Basel, Switzerland. Sedat Suna | Getty Images News | Getty Images Swiss pharmaceutical firm Roche is targeting becoming a top three obesity player globally, posing a potential rival to heavyweights Novo Nordisk and Eli Lilly as it advances one of its experimental weight-loss drugs to […]

Read More